Limits...
Detection of Serum Protein Biomarkers for the Diagnosis and Staging of Hepatoblastoma.

Zhao W, Li J, Zhang J, Gao P, Pei H, Wang L, Guo F, Yu J, Zheng S, Wang J - Int J Mol Sci (2015)

Bottom Line: Although the expression level decreased with increasing disease stage, pair-wise comparison revealed significant differences in Apo A-I expression between the normal group and the HB subgroups (p < 0.01).ELISA verified the reduced expression of Apo A-I in the HB group.Taken together, these results suggest that Apo A-I may represent a serum protein biomarker of HB.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Jianshe Road, Zhengzhou 450000, China. 13460300188@163.com.

ABSTRACT
The present study aimed to identify serum biomarkers for the detection of hepatoblastoma (HB). Serum samples were collected from 71 HB patients (stage I, n = 19; stage II, n = 19, stage III, n = 19; and stage IV, n = 14) and 23 age- and sex-matched healthy children. Differential expression of serum protein markers were screened using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), and the target proteins were isolated and purified using HPLC and identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), SEQUEST, and bioinformatics analysis. Differential protein expression was confirmed by enzyme-linked immunosorbent analysis (ELISA). SELDI-TOF-MS screening identified a differentially expressed protein with an m/z of 9348 Da, which was subsequently identified as Apo A-I; its expression was significantly lower in the HB group as compared to the normal control group (1546.67 ± 757.81 vs. 3359.21 ± 999.36, respectively; p < 0.01). Although the expression level decreased with increasing disease stage, pair-wise comparison revealed significant differences in Apo A-I expression between the normal group and the HB subgroups (p < 0.01). ELISA verified the reduced expression of Apo A-I in the HB group. Taken together, these results suggest that Apo A-I may represent a serum protein biomarker of HB. Further studies will assess the value of using Apo A-I expression for HB diagnosis and staging.

No MeSH data available.


Related in: MedlinePlus

SELDI-TOF-MS analysis of proteins or peptide segments with an m/z of 9348 Da in the normal and HB groups.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4490467&req=5

ijms-16-12669-f001: SELDI-TOF-MS analysis of proteins or peptide segments with an m/z of 9348 Da in the normal and HB groups.

Mentions: After screening the pretreated sera from the healthy children and HB patients using SELDI-TOF-MS, data from each protein peak and the peak values of the decomposed peptides were obtained. These protein peak values were standardized and analyzed using the Wilcoxon rank-sum test, and comparisons between the normal and HB groups were undertaken. Ten differentially expressed proteins, including four upregulated and six down-regulated protein peak values, were observed in the serum of HB patients (Table 1). A composite model with the highest Youden index was screened using the support vector machine (SVM) to obtain a protein marker with a Mass-to-charge ratio (m/z) of 9348 Da (Figure 1). The expression level of this marker was 3359.21 ± 999.36 and 1546.67 ± 757.81 in the normal control and HB groups, respectively (p < 0.01; Table 2). Analysis of the HB group by disease stage revealed that the expression level of the protein marker with an m/z of 9348 Da was significantly lower at each disease stage as compared with the normal group (p < 0.01; Table 2). Moreover, there were significant differences between HB subgroups (p < 0.01; Table 2). Figure 2 shows simulated electrophoretogram of proteins or peptide segments with an m/z of 9348 Da in the normal and HB groups with SELDI-TOF-MS. Using the method of leave-1-out for cross detection, the sensitivity of discriminating 71 HB and 23 normal subjects was 98.32%, and its specificity was 87.96%.


Detection of Serum Protein Biomarkers for the Diagnosis and Staging of Hepatoblastoma.

Zhao W, Li J, Zhang J, Gao P, Pei H, Wang L, Guo F, Yu J, Zheng S, Wang J - Int J Mol Sci (2015)

SELDI-TOF-MS analysis of proteins or peptide segments with an m/z of 9348 Da in the normal and HB groups.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4490467&req=5

ijms-16-12669-f001: SELDI-TOF-MS analysis of proteins or peptide segments with an m/z of 9348 Da in the normal and HB groups.
Mentions: After screening the pretreated sera from the healthy children and HB patients using SELDI-TOF-MS, data from each protein peak and the peak values of the decomposed peptides were obtained. These protein peak values were standardized and analyzed using the Wilcoxon rank-sum test, and comparisons between the normal and HB groups were undertaken. Ten differentially expressed proteins, including four upregulated and six down-regulated protein peak values, were observed in the serum of HB patients (Table 1). A composite model with the highest Youden index was screened using the support vector machine (SVM) to obtain a protein marker with a Mass-to-charge ratio (m/z) of 9348 Da (Figure 1). The expression level of this marker was 3359.21 ± 999.36 and 1546.67 ± 757.81 in the normal control and HB groups, respectively (p < 0.01; Table 2). Analysis of the HB group by disease stage revealed that the expression level of the protein marker with an m/z of 9348 Da was significantly lower at each disease stage as compared with the normal group (p < 0.01; Table 2). Moreover, there were significant differences between HB subgroups (p < 0.01; Table 2). Figure 2 shows simulated electrophoretogram of proteins or peptide segments with an m/z of 9348 Da in the normal and HB groups with SELDI-TOF-MS. Using the method of leave-1-out for cross detection, the sensitivity of discriminating 71 HB and 23 normal subjects was 98.32%, and its specificity was 87.96%.

Bottom Line: Although the expression level decreased with increasing disease stage, pair-wise comparison revealed significant differences in Apo A-I expression between the normal group and the HB subgroups (p < 0.01).ELISA verified the reduced expression of Apo A-I in the HB group.Taken together, these results suggest that Apo A-I may represent a serum protein biomarker of HB.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Jianshe Road, Zhengzhou 450000, China. 13460300188@163.com.

ABSTRACT
The present study aimed to identify serum biomarkers for the detection of hepatoblastoma (HB). Serum samples were collected from 71 HB patients (stage I, n = 19; stage II, n = 19, stage III, n = 19; and stage IV, n = 14) and 23 age- and sex-matched healthy children. Differential expression of serum protein markers were screened using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), and the target proteins were isolated and purified using HPLC and identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), SEQUEST, and bioinformatics analysis. Differential protein expression was confirmed by enzyme-linked immunosorbent analysis (ELISA). SELDI-TOF-MS screening identified a differentially expressed protein with an m/z of 9348 Da, which was subsequently identified as Apo A-I; its expression was significantly lower in the HB group as compared to the normal control group (1546.67 ± 757.81 vs. 3359.21 ± 999.36, respectively; p < 0.01). Although the expression level decreased with increasing disease stage, pair-wise comparison revealed significant differences in Apo A-I expression between the normal group and the HB subgroups (p < 0.01). ELISA verified the reduced expression of Apo A-I in the HB group. Taken together, these results suggest that Apo A-I may represent a serum protein biomarker of HB. Further studies will assess the value of using Apo A-I expression for HB diagnosis and staging.

No MeSH data available.


Related in: MedlinePlus